Upstream Bio Announces Dosing of First Patients in a Phase 2

Upstream Bio Announces Dosing of First Patients in a Phase 2 Clinical Trial of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio Announces Dosing of First Patients in a Phase 2 Clinical Trial of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , American , Sam Truex , Aaron Deykin , American Lung Association , Product Service , Head Of Research , Bio Announces Dosing , First Patients , Chronic Rhinosinusitis , Nasal Polyps , Chief Medical Officer , Upstream Bio , Chief Executive , Stromal Lymphopoietin , Lung Association ,